The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Survival Trends Higher With Necitumumab in EGFR FISH-Positive Squamous NSCLC
September 9th 2015Survival for patients with metastatic squamous non–small cell lung cancer whose tumors were positive for EGFR copy number as determined by FISH analysis tended to be better when the EGFR antibody necitumumab was added to their conventional chemotherapy.
Dr. Vokes on Screening, Epidemiology, and Smoking in Lung Cancer
September 7th 2015Everett E. Vokes, MD, chair, Department of Medicine, investigator of head and neck and lung cancer, University of Chicago, discusses a plenary session that covered prevention and screening at the 16th World Conference on Lung Cancer.
Dr. Axel Grothey on Differences Between CORRECT and CONCUR Studies in mCRC
July 16th 2015Axel Grothey, MD, department of Oncology, Mayo Clinic, Rochester, MN, discusses the differences between the CORRECT and CONCUR trials, which both looked at regorafenib for previously treated metastatic colorectal cancer (mCRC).
Dr. Manns on Risk Factors for Hepatitis C-Related Hepatocellular Carcinoma
July 7th 2015Michael Manns, MD, the Director of the Department of Gastroenterology, Hepatology and Endocrinology at the Medical School of Hannover in Germany, explains risk factors for hepatitis C-related hepatocellular carcinoma.
Survival Benefit of Regorafenib Confirmed in Combined Analysis of CORRECT and CONCUR
July 4th 2015The survival benefit observed with regorafenib (Stivarga) over placebo in Asian patients who had been previously treated for metastatic colorectal cancer in the international phase III CORRECT trial was confirmed by the phase III CONCUR trial.
Dr. Lorenza Rimassa on Tivantinib for EGFR Inhibitor-Resistant mCRC
July 4th 2015Lorenza Rimassa, MD, Deputy Director - Medical Oncology Unit - Humanitas Cancer Center, Humanitas Research Hospital, discusses a study looking at tivantinib (ARQ 197), a highly selective MET inhibitor, for the treatment of Metastatic Colorectal Cancer (mCRC).
Adding Aprepitant Improves Control of Oxaliplatin-Related Nausea, Vomiting in CRC
Adding an NK1 antagonist to a 5-HT3 receptor antagonist with dexamethasone improved antiemetic control for patients with colorectal cancer treated with an oxaliplatin-based regimen compared with the 5-HT3 antagonist and dexamethasone alone.
Dr. Eric Van Cutsem on Regorafenib for Metastatic Colorectal Cancer
July 3rd 2015Eric Van Cutsem, MD, PhD, of University Hospitals Gasthuisberg/Leuven, Leuven, Belgium, discusses the safety profile of the phase III B CONSIGN study, which looked at regorafenib in patients with previously treated metastatic colorectal cancer (mCRC).
Hepatitis C "Revolution" May Transform Liver Cancer Outcomes
July 2nd 2015Novel agents that target the replication of the hepatitis C virus are poised to have a far-reaching impact on the prevention and recurrence of hepatocellular carcinoma and have shown the ability to reverse liver fibrosis, including cirrhosis in patients with end-stage HCC.